Literature DB >> 28918492

Decreased plasma neuregulin 4 concentration is associated with increased high-sensitivity C-reactive protein in newly diagnosed type 2 diabetes mellitus patients: a cross-sectional study.

Pi-Jun Yan1, Yong Xu1, Qin Wan1, Jian Feng2, Hua Li1, Chen-Lin Gao1, Jun Yang1, Hai-Hua Zhong1, Zhi-Hong Zhang3.   

Abstract

AIMS: Inflammation has been reported to be involved in the pathogenesis of atherosclerosis. This principal objective of this study was to investigate if the secretion of neuregulin 4 (Nrg4), a soluble protein associated with metabolic syndrome and subclinical cardiovascular disease, is correlated with the inflammation marker high-sensitivity C-reactive protein (hs-CRP) in patients with newly diagnosed type 2 diabetes mellitus (nT2DM).
METHODS: A study group of 311 nT2DM patients was divided into three subgroups based on hs-CRP tertiles. Multiple linear regression was conducted to explore the association between plasma Nrg4 and hs-CRP levels.
RESULTS: The nT2DM patients with the highest hs-CRP levels (>2.46 mg/L) exhibited higher atherogenic coefficients and atherogenic index of plasma (AIP) levels, but lower levels of plasma Nrg4, as compared to those with the lowest hs-CRP levels (<0.63 mg/L). Plasma Nrg4 levels were inversely associated with white blood cell count, hs-CRP, and AIP and positively associated with high-density lipoprotein cholesterol (HDL-C), before and after adjustment for age, gender, body mass index (BMI), and body fat percentage (P < 0.01 or P < 0.05). hs-CRP was the factor most strongly associated with plasma Nrg4 levels.
CONCLUSIONS: These results indicate that lower plasma Nrg4 levels may be associated with elevated hs-CRP in nT2DM patients. It generates the hypothesis that decreased levels of Nrg4 may trigger the development of atherosclerosis through its proinflammatory effects. These findings need to be confirmed by further prospective studies.

Entities:  

Keywords:  Atherosclerosis; High-sensitivity C-reactive protein; Inflammation; Neuregulin 4; Newly diagnosed type 2 diabetes mellitus

Mesh:

Substances:

Year:  2017        PMID: 28918492     DOI: 10.1007/s00592-017-1044-4

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  6 in total

1.  ErbB4 deletion predisposes to development of metabolic syndrome in mice.

Authors:  Fenghua Zeng; Yinqiu Wang; Lance A Kloepfer; Suwan Wang; Raymond C Harris
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-06-26       Impact factor: 4.310

2.  Neuregulin 4 attenuate tubulointerstitial fibrosis and advanced glycosylation end products accumulation in diabetic nephropathy rats via regulating TNF-R1 signaling.

Authors:  Jinbao Shi; Weilong Xu; Ruiping Zheng; Huizi Miao; Qiaosheng Hu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

3.  Correlation between the levels of serum cystatin C and substance P in peripheral blood in diabetes mellitus patients complicated with hypertension.

Authors:  Wei Zhu; Xuelian Gong; Chao Luo; Jing Lu
Journal:  Exp Ther Med       Date:  2018-06-11       Impact factor: 2.447

4.  Elevated serum neuregulin 4 levels in patients with hyperthyroidism.

Authors:  Min Li; Ying Chen; Jingjing Jiang; Yan Lu; Zhiyi Song; Shengjie Zhang; Chao Sun; Hao Ying; Xiaofang Fan; Yuping Song; Jialin Yang; Lin Zhao
Journal:  Endocr Connect       Date:  2019-06-01       Impact factor: 3.335

5.  The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China.

Authors:  Zheng Qin; Kuo Zhou; Yueping Li; Wanjun Cheng; Zhijian Wang; Jianlong Wang; Fei Gao; Lixia Yang; Yingkai Xu; Yafeng Wu; Hua He; Yujie Zhou
Journal:  Cardiovasc Diabetol       Date:  2020-02-21       Impact factor: 9.951

Review 6.  Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.

Authors:  Andrew Geissler; Sergey Ryzhov; Douglas B Sawyer
Journal:  Clin Sci (Lond)       Date:  2020-10-16       Impact factor: 6.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.